About coya therapeutics inc - COYA
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing proprietary new therapies to enhance the function of regulatory T cells. Its pipeline includes Treg Modifying Biologics, Allogeneic Treg-Derived Exosomes, and Autologous Treg Cell Therapy. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.
COYA At a Glance
Coya Therapeutics, Inc.
5850 San Felipe Street
Houston, Texas 77057
| Phone | 1-800-587-8170 | Revenue | 7.95M | |
| Industry | Biotechnology | Net Income | -21,226,107.00 | |
| Sector | Health Technology | 2025 Sales Growth | 123.568% | |
| Fiscal Year-end | 12 / 2026 | Employees | 8 | |
| View SEC Filings |
COYA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.212 |
| Price to Book Ratio | 2.822 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.481 |
| Enterprise Value to Sales | 6.319 |
| Total Debt to Enterprise Value | N/A |
COYA Efficiency
| Revenue/Employee | 993,219.125 |
| Income Per Employee | -2,653,263.375 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.169 |
COYA Liquidity
| Current Ratio | 8.505 |
| Quick Ratio | 8.505 |
| Cash Ratio | 7.974 |
COYA Profitability
| Gross Margin | 99.656 |
| Operating Margin | -255.05 |
| Pretax Margin | -267.099 |
| Net Margin | -267.138 |
| Return on Assets | -45.02 |
| Return on Equity | -51.392 |
| Return on Total Capital | -49.331 |
| Return on Invested Capital | -51.392 |
COYA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |